CO2022011101A2 - Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismos - Google Patents
Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismosInfo
- Publication number
- CO2022011101A2 CO2022011101A2 CONC2022/0011101A CO2022011101A CO2022011101A2 CO 2022011101 A2 CO2022011101 A2 CO 2022011101A2 CO 2022011101 A CO2022011101 A CO 2022011101A CO 2022011101 A2 CO2022011101 A2 CO 2022011101A2
- Authority
- CO
- Colombia
- Prior art keywords
- same
- treatment methods
- disease treatment
- peptide compounds
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL272074A IL272074B2 (en) | 2020-01-15 | 2020-01-15 | Peptide compounds and methods of treating diseases using same |
| PCT/IL2021/050044 WO2021144798A1 (en) | 2020-01-15 | 2021-01-14 | Peptide compounds and methods of treating diseases using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022011101A2 true CO2022011101A2 (es) | 2022-11-08 |
Family
ID=76863930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0011101A CO2022011101A2 (es) | 2020-01-15 | 2022-08-04 | Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230049549A1 (enExample) |
| EP (1) | EP4090347A1 (enExample) |
| JP (1) | JP7809060B2 (enExample) |
| KR (1) | KR20220145826A (enExample) |
| CN (6) | CN119708144A (enExample) |
| AU (1) | AU2021207415A1 (enExample) |
| BR (1) | BR112022013978A2 (enExample) |
| CA (1) | CA3167139A1 (enExample) |
| CO (1) | CO2022011101A2 (enExample) |
| IL (1) | IL272074B2 (enExample) |
| MX (1) | MX2022008746A (enExample) |
| WO (1) | WO2021144798A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280101B2 (en) | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| WO2003037172A2 (en) * | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| AU2005276117C1 (en) * | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| US8648045B2 (en) * | 2005-03-10 | 2014-02-11 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | VDAC1 compositions and methods of use thereof for regulating apoptosis |
| CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| US20130096070A1 (en) * | 2009-04-07 | 2013-04-18 | University Of Kansas | Peptide targeting of inner ear cells |
| CA2836503C (en) * | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| IL280101B2 (en) * | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
-
2020
- 2020-01-15 IL IL272074A patent/IL272074B2/en unknown
-
2021
- 2021-01-14 US US17/792,787 patent/US20230049549A1/en active Pending
- 2021-01-14 EP EP21704023.7A patent/EP4090347A1/en active Pending
- 2021-01-14 CN CN202411888874.5A patent/CN119708144A/zh active Pending
- 2021-01-14 KR KR1020227028077A patent/KR20220145826A/ko active Pending
- 2021-01-14 JP JP2022542986A patent/JP7809060B2/ja active Active
- 2021-01-14 CN CN202411888865.6A patent/CN119708140A/zh active Pending
- 2021-01-14 CN CN202411888870.7A patent/CN119708142A/zh active Pending
- 2021-01-14 CN CN202411888869.4A patent/CN119708141A/zh active Pending
- 2021-01-14 CA CA3167139A patent/CA3167139A1/en active Pending
- 2021-01-14 CN CN202411888873.0A patent/CN119708143A/zh active Pending
- 2021-01-14 CN CN202180017719.4A patent/CN115942948B/zh active Active
- 2021-01-14 AU AU2021207415A patent/AU2021207415A1/en active Pending
- 2021-01-14 MX MX2022008746A patent/MX2022008746A/es unknown
- 2021-01-14 BR BR112022013978A patent/BR112022013978A2/pt unknown
- 2021-01-14 WO PCT/IL2021/050044 patent/WO2021144798A1/en not_active Ceased
-
2022
- 2022-08-04 CO CONC2022/0011101A patent/CO2022011101A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022008746A (es) | 2022-10-13 |
| WO2021144798A1 (en) | 2021-07-22 |
| CN119708141A (zh) | 2025-03-28 |
| JP7809060B2 (ja) | 2026-01-30 |
| CN115942948A (zh) | 2023-04-07 |
| CA3167139A1 (en) | 2021-07-22 |
| EP4090347A1 (en) | 2022-11-23 |
| US20230049549A1 (en) | 2023-02-16 |
| CN119708142A (zh) | 2025-03-28 |
| AU2021207415A1 (en) | 2022-09-08 |
| CN119708144A (zh) | 2025-03-28 |
| JP2023510019A (ja) | 2023-03-10 |
| IL272074B2 (en) | 2024-12-01 |
| CN119708143A (zh) | 2025-03-28 |
| IL272074A (en) | 2021-07-29 |
| CN115942948B (zh) | 2025-01-14 |
| BR112022013978A2 (pt) | 2022-10-11 |
| CN119708140A (zh) | 2025-03-28 |
| KR20220145826A (ko) | 2022-10-31 |
| IL272074B1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021003036A2 (es) | Compuestos de anillo fusionado | |
| CL2020002224A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil péptido | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| MX2018007089A (es) | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. | |
| CL2024000824A1 (es) | Composiciones y métodos de inhibición del masp-3 para tratar enfermedades y trastornos div 201900230 | |
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| AR111203A1 (es) | Inmunoconjugados | |
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| CL2018003322A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128) | |
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| MX2019004241A (es) | Composiciones y anticuerpos anti-gen 3 de activacion de linfocitos (lag-3). | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| BR112016023517A2 (pt) | produção de células t projetadas por transpóson sleeping beauty acoplado com seleção de metotrexato | |
| UY38200A (es) | Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos | |
| UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
| MX2019002998A (es) | Celulas t con resistencia incrementada a la inmunosupresion. | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| MX2018006635A (es) | Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona. | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa |